Poxel S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicolas Trouche
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Immeuble Le Sunway Lyon France 69007
- IPO Date
- Jan 6, 2017
- Website
- poxelpharma.com
- Similar Companies
- Business
- Poxel S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for chronic serious diseases linked to metabolic dysfunction, including metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and rare metabolic disorders. The company’s core products include TWYMEEG® (Imeglimin), a first-in-class oral drug targeting mitochondrial dysfunction, marketed for the treatment of type 2 diabetes in Japan through a strategic partnership with Sumitomo Pharma; PXL065, a deuterium-stabilized R-pioglitazone in Phase 2 clinical development for MASH; and PXL770, a pioneering direct adenosine monophosphate-activated protein kinase (AMPK) activator in Phase 2a for chronic metabolic diseases including non-alcoholic steatohepatitis (NASH), adrenoleukodystrophy (ALD), and autosomal dominant polycystic kidney disease (ADPKD). The company also holds licensing agreements for further development of farnesoid X receptor agonists and mitochondrial dysfunction therapies. Founded in 2009 and headquartered in Lyon, France, Poxel operates subsidiaries in Boston, Massachusetts, and Tokyo, Japan, focusing on key global markets in metabolic and rare diseases. Recent major changes include a non-dilutive financing agreement with OrbiMed in 2024 to monetize a portion of future royalties and sales-based payments from TWYMEEG® in Japan, raising USD 50 million to support activities in rare disease development, reduce debt, and fund general corporate purposes. The company has also finalized a recovery plan in 2025 focused on establishing new partnerships to commercialize Imeglimin in Asia, prioritizing China and other countries with streamlined regulatory requirements, alongside ongoing efforts to secure partnerships for PXL770 and PXL065. Poxel continues to advance its pipeline with strategic collaborations and strengthened financial positioning to support its growth in metabolic and rare disease segments. The company is listed on Euronext Paris (Ticker: POXEL).
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
Poxel Publishes Its Financial Results for the First Half of 2025
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
Poxel Reports Revenue for the Third Quarter 2025
Appointment of Yves Decadt as Member of Poxel's Board of Directors
Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading
Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan